Paul J. Diaz, President and CEO of Myriad, adds “PATHOMIQ’s technology platform, together with Myriad’s infrastructure and commercial capabilities allows for an accelerated pace of innovation to bring ...
Hosted on MSN1d
What To Expect From Myriad Genetics’s (MYGN) Q4 EarningsGenetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you ...
StockNews.com lowered shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research ...
SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...
Myriad Genetics (NASDAQ:MYGN – Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, February 25th. Analysts expect the company to announce earnings of $0 ...
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent ...
SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management ...
Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback